SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 1,760.18 |
Enterprise Value ($M) | 1,306.72 |
Book Value ($M) | 681.43 |
Book Value / Share | 5.18 |
Price / Book | 2.58 |
NCAV ($M) | 545.68 |
NCAV / Share | 4.15 |
Price / NCAV | 3.23 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | 0.02 |
Return on Assets (ROA) | 0.02 |
Return on Equity (ROE) | 0.03 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 12.34 |
Current Ratio | 13.23 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 926.24 |
Assets | 1,061.99 |
Liabilities | 380.56 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | 0.00 |
Net Income | 0.00 |
Earnings Per Share Basic And Diluted | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 0.00 |
Cash from Investing | 0.00 |
Cash from Financing | 0.00 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G | Kynam Capital Management, LP | 6.34 | ||
13G/A | BlackRock, Inc. | 16.00 | 0.00 | |
13D/A | Deep Track Capital, LP | 13.60 | 42.03 | |
13G/A | State Street Corp | 5.90 | -19.01 | |
13G/A | Federated Hermes, Inc. | 4.70 | -45.81 | |
13G/A | Vanguard Group Inc | 7.18 | 11.16 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
4,347,031 | 7,205,236 | 60.33 | |
775,551 | 2,155,634 | 35.98 | |
291,828 | 1,557,833 | 18.73 | |
893,095 | 2,620,979 | 34.07 | |
(click for more detail) |
Similar Companies | |
---|---|
DAWN – Day One Biopharmaceuticals, Inc. | DNLI – Denali Therapeutics Inc. |
DSGN – Design Therapeutics, Inc. | EDIT – Editas Medicine, Inc. |
ELEV – Elevation Oncology, Inc. |